8-K: ZEO SCIENTIFIX Names Dr. John Kisiday Chief Science Officer

Zeo ScientifiX, Inc. announced the appointment of Dr. John D. Kisiday, Ph.D., a veteran in tissue engineering and regenerative medicine, as its new Chief Science Officer.

Summary

• Dr. John D. Kisiday, Ph.D., was appointed Chief Science Officer (CSO) of Zeo ScientifiX, Inc., effective January 23, 2026.
• Dr. Kisiday brings almost 30 years of experience in the development and translation of tissue-engineering and regenerative-medicine therapies, particularly for orthopedic applications.
• His compensation package includes a base salary of $175,000 per annum.
• He was awarded a stock grant of 50,000 shares of common stock under the company's 2021 Incentive Plan, with 20,000 shares vesting on the first anniversary and 30,000 shares on the second anniversary of the Employment Agreement, contingent on continued employment.
• The employment is 'At Will,' but Dr. Kisiday is entitled to severance equal to one-quarter month's salary for each successive three months of employment completed, if terminated without Cause or if he terminates for Good Reason after the initial 90-day period.
• Initially, Dr. Kisiday will perform duties remotely from Fort Collins, CO, but is expected to relocate to Florida and spend significant time at the company's headquarters in Davie, Florida.
• The CSO's responsibilities include scientific leadership, strategic oversight of research initiatives, managing laboratory operations, overseeing clinical research (including FDA trials and IRB studies), and participating in market education efforts.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced Chief Science Officer is a positive strategic move, strengthening the company's scientific leadership and potential for innovation. While it's a standard operational event rather than a transformative financial one, it signals a commitment to advancing the company's core business.

Positives

• Appointment of a highly experienced Chief Science Officer, Dr. John D. Kisiday, with nearly 30 years in tissue engineering and regenerative medicine, significantly strengthening the company's scientific leadership.
• Dr. Kisiday's broad expertise in basic research, cell-therapy development, and generation of high-quality scientific data is crucial for advancing the company's product pipeline.
• The employment agreement includes a 'New Opportunity Bonus' where Dr. Kisiday may receive additional compensation (expected to be a royalty) for bringing commercially viable new products or business opportunities outside the current scope.
• The CSO role emphasizes strategic oversight, rigorous scientific innovation, and the translation of research into effective laboratory execution, which is vital for growth.
• A clear focus on advancing FDA clinical trials, IRB studies, and real-world evidence studies is outlined, aiming for regulatory approval and market acceptance of products.
• Commitment to market education efforts, including conferences, webinars, and peer-to-peer interfacing, to build interest and adoption of the company's biologics.

Negatives

• The employment is 'At Will,' meaning the company can terminate Dr. Kisiday's employment at any time, for any reason or no reason, with or without Cause, which could introduce instability.
• A non-competition clause restricts Dr. Kisiday from engaging in competitive businesses for two years post-employment, potentially limiting his future career options.
• Dr. Kisiday is expected to relocate from Fort Collins, CO, to Florida and spend significant time at the company's headquarters, which could present personal or logistical challenges.

Risks

• Key Personnel Risk: The company's scientific advancement and product development are highly dependent on the expertise and leadership of the new CSO, Dr. Kisiday. The 'At Will' nature of his employment introduces a risk of sudden departure or termination.
• Relocation and Integration Risk: The expectation for Dr. Kisiday to relocate and spend significant time at headquarters could lead to unforeseen challenges or delays in his full integration and operational effectiveness.
• Competitive Landscape: The non-compete clause highlights the competitive nature of the regenerative medicine industry, requiring the company to continuously innovate and protect its intellectual property.
• Regulatory Hurdles: The CSO's role involves navigating complex and time-consuming FDA clinical trials and other regulatory approvals, which carry inherent risks of delays, increased costs, or failure.
• Intellectual Property Protection: The extensive clauses on Work Product and Confidential Information underscore the critical importance of protecting the company's proprietary science and technology, which is a continuous risk.

Future Outlook

The company plans to leverage Dr. Kisiday's expertise to drive scientific innovation, evaluate and advance new research initiatives, oversee FDA clinical trials and other studies for regulatory approval, and expand market education efforts for its biologics. The future outlook includes a clear focus on developing new commercially viable products, optimizing existing ones, and expanding potential markets based on current R&D, intellectual property, and regulatory compliance.

Management Comments

• The company desires to secure the services of the Executive, and the Executive desires to furnish such services to the company on and subject to the terms and conditions set forth in the Agreement.
• The company expects the Executive to be physically present at the company’s headquarters on a regular basis, especially initially to achieve immediate tasks.
• The CSO serves as the company’s senior scientific authority, responsible for ensuring that scientific innovation is rigorous, feasible, aligned with organizational strategy, and executed responsibly.

Industry Context

The appointment of a Chief Science Officer with deep experience in tissue engineering and regenerative medicine signals Zeo ScientifiX's continued commitment to innovation in the orthobiologics and biomaterials sector. This aligns with a broader industry trend of increasing investment in advanced therapies for musculoskeletal conditions and age-related degeneration, where strong scientific leadership is critical for successful product development, regulatory navigation, and market penetration.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The appointment of a highly experienced CSO could lead to enhanced scientific innovation, more efficient product development, and improved regulatory outcomes, potentially driving long-term shareholder value.
• Employees: New scientific leadership may introduce new strategies, processes, and a focus on collaboration and continuous improvement within the R&D and laboratory operations.
• Customers/Patients: The focus on advancing clinical trials and developing new therapies could lead to the availability of new and improved regenerative medicine products.
• Regulatory Bodies: The emphasis on FDA clinical trials, compliance, and obtaining necessary registrations signals a commitment to meeting regulatory standards, which is positive for regulatory relationships.

Next Steps

• Dr. Kisiday to gain a thorough understanding of the company's laboratory operations, including research, manufacturing, quality control, and distribution.
• Dr. Kisiday to assess the capacity, roles, and responsibilities of all lab personnel and make recommendations for potential changes.
• Dr. Kisiday to install policies and procedures to provide required oversight, effectiveness, and controls over laboratory operations.
• Develop a culture within the lab for creativity and timeliness of results.
• Manage the company's clinical research program, including conducting and completing FDA clinical trials, IRB studies, and/or real-world evidence studies.
• Develop and participate in physician and consumer market education efforts to build interest and adoption of the company's biologics.
• Maintain relationships with Key Opinion Leaders (KOLs), scientific advisors, and academic partners.
• Oversee compliance with regulations for the manufacturing and sales of the company's products and identify growth opportunities.
• Manage efforts to obtain and maintain necessary registrations, accreditations, and licenses (e.g., FDA, AABB, AATB).
• Collaborate with existing teams on R&D efforts, including desired modifications to existing products, development of new products, and expansion of potential markets.

Key Dates

Keywords

Chief Science Officer, CSO, John D. Kisiday, Zeo ScientifiX, Regenerative Medicine, Tissue Engineering, Orthobiologics, Biomaterials, SEC 8-K, Employment Agreement, Corporate Governance, Biotech, Medical Devices, Clinical Trials, FDA